Skip Navigation

Cardiovascular Research 2007 75(3):530-535; doi:10.1016/j.cardiores.2007.04.022
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lim, S. Y.
Right arrow Articles by Yellon, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, S. Y.
Right arrow Articles by Yellon, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore

Shiang Y. Lim, Sean M. Davidson, Derek J. Hausenloy and Derek M. Yellon*

The Hatter Cardiovascular Institute, University College London Hospital and Medical School, 67 Chenies Mews, London WC1E 6HX, UK

* Corresponding author. Tel.: +44 207 380 9888; fax: +44 207 388 5095. d.yellon{at}ucl.ac.uk

Objective The opening of the mitochondrial permeability transition pore (mPTP) at the time of myocardial reperfusion is a critical determinant of cell death. Emerging studies suggest that suppression of mPTP opening may underlie the cardioprotection elicited by both ischemic preconditioning (IPC) and postconditioning (IPost). To further evaluate the role of the mPTP in cardioprotection, we hypothesized that hearts deficient in cyclophilin-D (CYP-D–/–), a key component of the mPTP, will be resistant to cardioprotection conferred by ischemic and pharmacological preconditioning and postconditioning.

Methods and results Male/female wild type or CYP-D–/– mice were subjected to 30 min of ischemia and 120 min of reperfusion. In wild type mice subjected to in vivo myocardial ischemia–reperfusion injury, a significant reduction in myocardial infarct size was observed with the following treatments (n≥6/group; P<0.05): (1) IPC (28±4% vs. 46.2±4% in control); (2) Diazoxide (5 mg/kg) pre-treatment (26.4±3% vs. 54±10% in vehicle control); (3) IPost-1 or IPost-2, three or six 10-s cycles of ischemia–reperfusion (27.2±3% and 32±4%, respectively vs. 46.2±4% in control); (4) Bradykinin (40 µg/kg) (28.3±1% vs. 48±4% in vehicle control); (5) cyclosporin-A (10 mg/kg) (32.3±3% vs. 48±4% in vehicle control) (6) sanglifehrin-A (25 mg/kg) (29.3±3% vs. 48±4% in vehicle control). Interestingly, however, no infarct-limiting effects were demonstrated in CYP-D–/– mice with the same treatment protocols: (27.9±5% in control vs. 31.2±7% with IPC, 30.2±5% with IPost-1, 24.7±8% with IPost-2; 30.1±4% in vehicle control vs. 26.4±7% with diazoxide; 24.6±4% in vehicle control vs. 24.9±5% with bradykinin, 26.8±7% with cyclosporin-A, 32.5±6% with sanglifehrin-A: n≥6/group: P>0.05).

Conclusion This study demonstrates that the mPTP plays a critical role in the cardioprotection elicited by ischemic and pharmacological preconditioning and postconditioning.

KEYWORDS Ischemia; Mitochondria; Reperfusion; Preconditioning


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
L. Gomez, B. Li, N. Mewton, I. Sanchez, C. Piot, M. Elbaz, and M. Ovize
Inhibition of mitochondrial permeability transition pore opening: translation to patients
Cardiovasc Res, July 15, 2009; 83(2): 226 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen
Protective ischaemia in patients: preconditioning and postconditioning
Cardiovasc Res, July 15, 2009; 83(2): 234 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Krieg, Y. Liu, T. Rutz, C. Methner, X.-M. Yang, T. Dost, S. B. Felix, J.-P. Stasch, M. V. Cohen, and J. M. Downey
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
Eur. Heart J., July 1, 2009; 30(13): 1607 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Huhn, A. Heinen, N. C. Weber, R. P. Kerindongo, G. T. M. L. Oei, M. W. Hollmann, W. Schlack, and B. Preckel
Helium-Induced Early Preconditioning and Postconditioning Are Abolished in Obese Zucker Rats in Vivo
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 600 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
Y. Nishino, I. G. Webb, S. M. Davidson, A. I. Ahmed, J. E. Clark, S. Jacquet, A. M. Shah, T. Miura, D. M. Yellon, M. Avkiran, et al.
Glycogen Synthase Kinase-3 Inactivation Is Not Required for Ischemic Preconditioning or Postconditioning in the Mouse
Circ. Res., August 1, 2008; 103(3): 307 - 314.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
E. Murphy and C. Steenbergen
Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury
Physiol Rev, April 1, 2008; 88(2): 581 - 609.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.